Carcinoma  >>  Signifor LAR (pasireotide long acting release)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Signifor LAR (pasireotide long acting release) / Recordati
NCT00690430 / 2007-000739-25: Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Completed
3
186
US, Canada, Europe, RoW
Pasireotide, SOM230, Octreotide, Sadostatin LAR
Novartis Pharmaceuticals
Symptomatic Refractory Resistant Carcinoid Disease
04/12
04/12

Download Options